指南与共识乳腺癌

HR+/HER-2-早期乳腺癌复发风险与临床管理专家共识(2025版)

[Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2025-01-01

本共识由国家肿瘤质控中心乳腺癌专家委员会、中国抗癌协会肿瘤药物临床研究专业委员会和中国抗癌协会乳腺癌专业委员会制定,聚焦HR+/HER-2-早期乳腺癌复发风险分层与临床管理,结合国内外研究进展及专家意见,为复发风险评估和个体化辅助强化治疗提供标准化参考。

要点

  • HR+/HER-2-乳腺癌约占全部乳腺癌的70%,绝大多数初诊为早期乳腺癌。
  • 伴高危因素的淋巴结阴性患者术后5年复发率可达15%,与N1患者相似。
  • 治疗模式从传统内分泌治疗演进为有选择的内分泌联合靶向强化治疗策略。

核心结论

  • 共识旨在为HR+/HER-2-早期乳腺癌患者的复发风险分层和临床管理提供标准化参考,进一步提高治疗获益和生活质量,最大化治愈可能。

研究设计与样本

  • 由国家肿瘤质控中心乳腺癌专家委员会、中国抗癌协会肿瘤药物临床研究专业委员会和中国抗癌协会乳腺癌专业委员会制定,结合国内外早期乳腺癌临床研究进展及专家意见形成。

主要发现

  • HR+/HER-2-乳腺癌是最常见亚型,约占全部乳腺癌的70%,绝大多数患者首次确诊时为早期乳腺癌。
  • 中国早期乳腺癌Ⅱ~Ⅲ期患者占比较高,且发病年龄较为年轻。
  • 即使经过标准内分泌治疗,患者仍面临短期和长期复发风险,且复发风险终身存在。
  • 国家癌症中心等国内外大规模真实世界研究显示,Ⅱ~Ⅲ期HR+/HER-2-早期乳腺癌中淋巴结阳性和伴高危因素的淋巴结阴性患者复发和死亡风险显著更高。
  • 伴高危因素的淋巴结阴性患者术后5年复发率可达15%,与N1患者复发率相似。

临床怎么用

  • 共识指出复发风险的精准评估指导治疗决策优化至关重要,治疗模式从传统内分泌治疗逐步演进为有选择的内分泌联合靶向的强化治疗策略。
  • 共识旨在帮助临床医师科学、精准地评估复发风险,为患者量身定制个体化的辅助强化治疗方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer is the most common malignancy among women worldwide, with relatively high morbidity and mortality rates among Chinese women, posing a serious threat to female health. HR+/HER-2- breast cancer is the most common subtype, accounting for approximately 70% of all breast cancers. The vast majority of patients are diagnosed with early breast cancer (EBC) at initial presentation. Stage Ⅱ-Ⅲ EBC constitutes a substantial proportion of cases among Chinese patients, with a significantly younger age of onset observed nationally. Even after standard endocrine therapy, patients still face short-term and long-term recurrence risks, and the risk of recurrence persists lifelong. In recent years, large-scale real-world studies from the National Cancer Center and other institutions, both domestically and internationally, have shown that for stage Ⅱ-Ⅲ HR+/HER-2- EBC patients, those with lymph node positivity and lymph node negative patients with high-risk factors have a significantly higher risk of recurrence and death. The postoperative 5-year recurrence rate for lymph node negative patients with high-risk factors can reach 15%, similar to the recurrence rate of N1 patients. These findings have updated the clinical understanding of defining high-risk patients and raised new requirements for EBC recurrence risk assessment and definition. On the other hand, the clinical management of recurrence risk in early HR+/HER-2- breast cancer has consistently received significant attention. From the initial adjuvant chemotherapy to the entire process of adjuvant endocrine therapy, in recent years, with the publication of clinical trial results for novel targeted agents such as CDK4/6 inhibitors (CDK4/6i) and PARP inhibitors (PARPi) and the subsequent approval of their indications, the treatment paradigm for HR+/HER-2- EBC has gradually evolved from traditional endocrine therapy to a selective strategy of intensified treatment combining endocrine therapy with targeted agents. This underscores the critical importance of precise recurrence risk assessment and optimization of treatment decisions. To assist clinicians in scientifically and accurately assessing recurrence risk and tailoring individualized intensified adjuvant treatment regimens for patients, the Breast Cancer Expert Committee of the National Cancer Quality Control Center, the Professional Committee of Drug Clinical Research of Chinese Anti-Cancer Association, and the Professional Committee of Breast Cancer of the Chinese Anti-Cancer Association, incorporating advances in clinical research on early breast cancer both domestically and internationally and expert opinions, have formulated the "Consensus on Recurrence Risk and Clinical Management of HR+/HER-2- Early Breast Cancer(2025 edition)". It aims to provide a standardized reference for recurrence risk stratification and clinical management of HR+/HER-2-EBC patients, further enhancing patient treatment benefits and quality of life, and maximizing the potential for cure. 乳腺癌是全球女性中最常见的恶性肿瘤,中国女性中乳腺癌的发病率和死亡率较高,严重威胁女性健康。激素受体阳性(HR+)/人表皮生长因子受体2阴性(HER-2-)乳腺癌是最常见的亚型,约占全部乳腺癌的70%,绝大多数患者在首次确诊时为早期乳腺癌(EBC)。中国EBC Ⅱ~Ⅲ期患者占比较高,且发病年龄较为年轻。即使经过标准内分泌治疗,仍然面临短期和长期复发风险,且复发风险终身存在。近年来,国家癌症中心等进行的国内外大规模真实世界研究显示,对于Ⅱ~Ⅲ期HR+/HER-2- EBC患者,淋巴结阳性和伴高危因素的淋巴结阴性患者的复发和死亡风险显著更高;伴高危因素的淋巴结阴性患者术后5年复发率可达15%,与N1患者复发率相似。这些发现更新了临床上对于高复发风险患者界定的认知,并对EBC复发风险评估和界定提出了新要求。另一方面,对于早期HR+/HER-2-乳腺癌复发风险的临床管理一直备受关注与重视,从最初的辅助化疗到辅助内分泌治疗全过程,近年来,随着CDK4/6抑制剂和PARP抑制剂等新型靶向药物临床研究结果的公布及其适应证的相继获批,HR+/HER-2- EBC的治疗模式从传统内分泌治疗逐步演进为有选择的内分泌联合靶向的强化治疗策略,提示复发风险的精准评估指导治疗决策优化至关重要。为帮助临床医师科学、精准地评估复发风险,为患者量身定制个体化的辅助强化治疗方案,国家肿瘤质控中心乳腺癌专家委员会、中国抗癌协会肿瘤药物临床研究专业委员会和中国抗癌协会乳腺癌专业委员会结合国内外EBC临床研究进展及专家意见,形成了《HR+/HER-2-早期乳腺癌复发风险与临床管理专家共识(2025版)》,旨在为HR+/HER-2- EBC患者的复发风险分层和临床管理提供标准化参考,进一步提高患者治疗获益和生活质量,最大化治愈可能。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40692249. doi:10.3760/cma.j.cn112152-20250524-00240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。